AstraZeneca has announced that it will begin selling the lung cancer drug sunvozertinib, following criticism over delays in bringing this medicine, originally developed in China, to the U.S. market. This comes amid reports of desperate Americans traveling to China to obtain the drug, which had received FDA approval but was unavailable in the U.S. for over a year.
Max Doppelt, a cancer treatment advocate, shared his experience of traveling to Shanghai to secure the drug for his mother, who was battling advanced lung cancer. He noted that the drug could have been easily accessible in China, highlighting the frustrations faced by patients in the U.S.
Sunvozertinib, developed by Dizal Pharmaceutical in China, targets advanced lung cancer and offers another treatment alternative. AstraZeneca secured the rights to market and develop the drug under the name Zegfrovy, following a significant financial agreement with Dizal.
Despite the political tensions between the U.S. and China, Doppelt successfully returned with the drug, which he indicated saved his mother’s life. AstraZeneca explained that their licensing agreement was completed in September 2026, and they aimed to make Zegfrovy available in the U.S. as soon as possible.
Doppelt expressed frustration over the delays in U.S. availability, while acknowledging that without AstraZeneca’s involvement, the drug might not exist in the market at all. Experts have emphasized the need for the U.S. to adapt its approach to drug approval processes to ensure that patients have timely access to innovative treatments, learning from China’s advancements in the pharmaceutical sector.
